Date Published:
2014 Mar

Publication Type:
Journal Article

Authors:

I. Mocchetti
A. Bachis
L.A. Campbell
V. Avdoshina

Secondary:
J Neuroimmune Pharmacol

Volume:
9

Pagination:
80-91

Issue:
2

PMID:
23832285

URL:
https://pubmed.ncbi.nlm.nih.gov/23832285

DOI:
10.1007/s11481-013-9488-y

Keywords:
AIDS Dementia Complex;Animals;Brain;Brain-derived neurotrophic factor;External;Humans;Nerve Growth Factors;Neuronal Plasticity

Abstract:
<p>Human immunodeficiency virus type-1 (HIV) causes mild or severe neurological problems, termed HIV-associated neurocognitive disorder (HAND), even when HIV patients receive antiretroviral therapy. Thus, novel adjunctive therapies are necessary to reduce or abolish the neurotoxic effect of HIV. However, new therapies require a better understanding of the molecular and cellular mechanisms of HIV-induced neurotoxicity. HAND subjects are characterized by being profoundly depressed, and they experience deficits in memory, learning and movements. Experimental evidence has also shown that HIV reduces neurogenesis. These deficits resemble those occurring in premature brain aging or in a brain with impaired neural repair properties. Thus, it appears that HIV diminishes neuronal survival, along with reduced neuronal connections. These two phenomena should not occur in the adult and developing brain when synaptic plasticity is promoted by neurotrophic factors, polypeptides that are present in adult synapses. This review will outline experimental evidence as well as present emerging concepts for the use of neurotrophic factors and in particular brain-derived neurotrophic factor as an adjunct therapy to prevent HIV-mediated neuronal degeneration and restore the loss of synaptic connections.</p>